Intrexon (XON) Stock Price Up 4.5%

Intrexon Corp (NYSE:XON) rose 4.5% during mid-day trading on Wednesday . The company traded as high as $13.15 and last traded at $13.61. Approximately 1,176,847 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 2,375,250 shares. The stock had previously closed at $13.02.

XON has been the topic of a number of research reports. Zacks Investment Research cut Intrexon from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. ValuEngine cut Intrexon from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Northland Securities reiterated a “buy” rating and set a $21.00 price target on shares of Intrexon in a research report on Friday, November 10th. Stifel Nicolaus upped their price target on Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, November 10th. Finally, Bank of America decreased their price target on Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $38.50.

The stock has a market cap of $1,720.00, a PE ratio of -12.13 and a beta of 1.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.85 and a current ratio of 2.05.

Intrexon (NYSE:XON) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%. equities research analysts expect that Intrexon Corp will post -1.06 earnings per share for the current fiscal year.

In related news, CEO Randal J. Kirk purchased 1,000,000 shares of the firm’s stock in a transaction dated Friday, January 19th. The shares were purchased at an average cost of $12.50 per share, for a total transaction of $12,500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 56.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. grew its holdings in shares of Intrexon by 0.6% during the second quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 200 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Intrexon by 4.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 59,146 shares of the biotechnology company’s stock worth $1,425,000 after purchasing an additional 2,468 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Intrexon by 1.4% during the third quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock worth $4,512,000 after purchasing an additional 3,234 shares in the last quarter. Advisor Group Inc. grew its holdings in shares of Intrexon by 61.5% during the second quarter. Advisor Group Inc. now owns 8,797 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 3,351 shares in the last quarter. Finally, Teachers Advisors LLC grew its holdings in shares of Intrexon by 7.9% during the second quarter. Teachers Advisors LLC now owns 57,840 shares of the biotechnology company’s stock worth $1,393,000 after purchasing an additional 4,234 shares in the last quarter. 73.31% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/02/08/intrexon-xon-stock-price-up-4-5.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit